WP
CEROW

Woodline Partners’s CERo Therapeutics Warrants CEROW Stock Holding History

Woodline Partners’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,500
Closed -$1K – 855
2022
Q3 		$1K Hold
12,500
– – ﹤0.01% 731
2022
Q2 		$1K Hold
12,500
– – ﹤0.01% 787
2022
Q1 		$2K Hold
12,500
– – ﹤0.01% 707
2021
Q4 		$5K Buy
+12,500
New +$5.76K ﹤0.01% 694

Other funds holding CEROW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Woodline Partners's CEROW Position: Q4 2022 in Review

Woodline Partners sold out of CERo Therapeutics Warrants (CEROW) in Q4 2022, closing a stake of 12,500 shares — an estimated $1K sold.

Woodline Partners first reported a position in CEROW in Q4 2021 and held it in 4 quarters. The position peaked at $5K in Q4 2021. 49 funds tracked by Wall St. Rank hold CEROW as of Q4 2022.

  • Woodline Partners reported no remaining CERo Therapeutics Warrants position as of Q4 2022 after selling out during the quarter.
  • Woodline Partners sold 12,500 CERo Therapeutics Warrants shares in Q4 2022, an estimated $1K.
  • Woodline Partners first reported a position in CERo Therapeutics Warrants in Q4 2021 and held it in 4 quarters.
  • Woodline Partners's CERo Therapeutics Warrants position peaked at $5K in Q4 2021.
  • 49 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2022.

Based on Woodline Partners's 13F filing for Q4 2022, filed 14 Feb 2023.